TITLE

HEPATITIS ;C'; ASSOCIATION OF INTERFERON-RIBAVIRIN THERAPY WITH HEARING LOSS

AUTHOR(S)
Khan, Muzaffar Mehmood; Bhatti, Muhammad Ali; Tahir, Muhammad; Khokar, Muhammad Riaz; Raza, Mohsin
PUB. DATE
April 2012
SOURCE
Professional Medical Journal;Mar/Apr2012, Vol. 19 Issue 2, p193
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Objective: The objective of this study was to determine association of Interferon-Ribavarin therapy with hearing loss in patients suffering from Hepatitis 'C'. Study Design: Quasi-experimental study. Place and Duration: Otolaryngology Department Combined Military Hospital Rawalpindi from 09 June 2006 to 08 June 2007. Patients and Methods: Consenting sixty patients of Hepatitis C divided into two equal groups of 30 each, (group A receiving Interferon-Ribavarin therapy and group B, not receiving it) during the study period fitting the inclusion criteria were selected. Pure Tone Audiometery including both air and bone conduction performed as base line data at commencement of therapy and then at the end of therapy (after six months) . Patients were sampled by Convenience (non-probability) technique. Results: The number of patients who were found to have defined hearing loss was 06 (20%) in Group A (n=30) and 05(16.67%) in Group B (n=30). Chi Square test was applied which showed a p-value of 0.739 which is highly insignificant. Conclusions: Interferon-Ribavarin Therapy does not have a significant association with hearing loss in patients of Hepatitis 'C'
ACCESSION #
76115836

 

Related Articles

  • Sudden Hearing Loss in Patients with Chronic Hepatitis C Treated with Pegylated Interferon/Ribavirin. Formann, Elisabeth; Stauber, Rudolf; Denk, Doris-Maria; Jessner, Wolfgang; Zollner, Gernot; Munda-Steindl, Petra; Gangl, Alfred; Ferenci, Peter // American Journal of Gastroenterology;May2004, Vol. 99 Issue 5, p873 

    BACKGROUND: Sudden hearing loss has been reported on standard interferon (IFN)-α2 therapy. This is the first report on the occurrence of sudden hearing loss in six cases of chronic hepatitis C in temporal relation to treatment with pegylated (PEG)-IFN alfa2a or b/ribavirin combination...

  • Real Response to Therapy in Chronic Hepatitis C Virus Patients: A Study From Iran. Namazee, Najmeh; Sali, Shahnaz; Asadi, Sorour; Shafiei, Mostafa; Behnava, Bita; Alavian, Seyed Moayed // Hepatitis Monthly;2012, Vol. 12 Issue 9, p1 

    Background: Despite significant advances in the treatment of chronic hepatitis C in the past decades, factors which can affect response rates to combination therapy; peginterferon and ribavirin, are still under study and reaching sustained virological response (SVR) is affected by several...

  • A Watershed Moment in the Treatment of Hepatitis C. Chung, Raymond T. // New England Journal of Medicine;1/19/2012, Vol. 366 Issue 3, p273 

    The article presents an update on the treatment of hepatitis C in the U.S. as of 2011. It says that treatment of chronic hepatitis C infection has relied on the use of the nonspecific antiviral cytokine interferon alfa for over 20 years. According to the author, medicine is on the threshold of a...

  • Hepatitis C Treatment: Trial by Design. Bzeizi, Khalid I. // Saudi Journal of Gastroenterology;Apr-Jun2008, Vol. 14 Issue 2, p51 

    The author comments on the findings of a study about the treatment outcome of 335 hepatitis C virus (HCV) patients treated with peginterferon α-2a and ribavirin combination therapy in Saudi Arabia. He states that the divergence of the study's findings from the prospective studies published...

  • Enhanced anti-HCV activity of interferon alpha 17 subtype. Dubois, Aurelie; François, Catherine; Descamps, Veronique; Fournier, Carole; Wychowski, Czeslaw; Dubuisson, Jean; Castelain, Sandrine; Duverlie, Gilles // Virology Journal;2009, Vol. 6, p1 

    Background: Pegylated interferon alpha 2 (a or b) plus ribavirin is the most effective treatment of chronic hepatitis C but a large proportion of patients do not respond to therapy. So, it is interesting to improve the treatment efficacy. Interferon alpha is a type I interferon composed of 12...

  • Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C. Wong, John B.; Davis, Gary L.; McHutchison, John G.; Manns, Michael P.; Albrecht, Janice K. // American Journal of Gastroenterology;Nov2003, Vol. 98 Issue 11, p2354 

    : ObjectivesEvaluation of 12-wk viral response to initial antiviral therapy for chronic hepatitis C has been recommended to minimize antiviral-associated morbidity and costs. The aim of this study was to examine the economic and clinical effects of evaluating rapid viral response during...

  • Ribavirin concentration in the later stages of 48 week pegylated interferon-α2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response. Furusyo, Norihiro; Murata, Masayuki; Ogawa, Eiichi; Toyoda, Kazuhiro; Ihara, Takeshi; Ikezaki, Hiroaki; Hayashi, Takeo; Koga, Tsunehisa; Kainuma, Mosaburo; Hayashi, Jun // Journal of Antimicrobial Chemotherapy (JAC);May2011, Vol. 66 Issue 5, p1127 

    Objectives The current standard of care for chronic hepatitis C patients is a pegylated interferon-α plus ribavirin combination treatment. This study was carried out to determine the relationship between ribavirin concentration in the later stages of treatment and virological relapse....

  • Peginterferon-Based Therapy for Chronic Hepatitis C Virus Infection in Patients with Normal Alanine Aminotransferase Levels. Brillanti, Stefano; Levantesi, Fabio; Nigro, Giovanni; Vicari, Susanna; Roda, Enrico // Annals of Internal Medicine;12/2/2003, Vol. 139 Issue 11, pE-959 

    Evaluates whether the use of peginterferon-based antiviral therapy (ALT) is beneficial in patients with chronic hepatitis C virus (HCV) infection and persistently normal ALT values. Methods and findings; Effectiveness of combination therapy; Progression of chronic HCV infection toward advanced...

  • Peginterferon-α-2a (40kD) plus ribavirin: a new treatment option takes flight in chronic hepatitis C.  // Drugs & Therapy Perspectives;Feb2004, Vol. 20 Issue 2, p1 

    Combination therapy with peginterferon-α-2a (40kD) [Pegasys®] plus ribavirin (Copegus™, Rebetol®) is a valuable new option for the first-line treatment of chronic hepatitis C. With regard to the sustained virological response rate, peginterferon-α-2a (40kD) plus ribavirin...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics